Tags

Type your tag names separated by a space and hit enter

The combined effect of parathyroid hormone (1-34) and whole-body vibration exercise on physical performance in OSteoporotic women (PaVOS study): a secondary analysis from a randomised controlled trial.

Abstract

Background

The aim of this study was to investigate the effect on physical performance of combining whole-body vibration exercise (WBV) with parathyroid hormone 1-34 (teriparatide) compared to teriparatide alone.

Methods

A secondary analysis from a RCT where postmenopausal women with severe osteoporosis were randomised to WBV plus teriparatide (intervention) or teriparatide alone (control). WBV was applied three times/week (6x1min WBV:1 min rest, (peak acceleration 3.6 g)) for twelve months. Both groups received teriparatide 20 μg s.c./day. The primary endpoint (bone mineral density) is reported elsewhere. Physical performance measures (Short Physical Performance Battery (SPPB), Timed-Up-and-Go (TUG), leg extension power, and grip strength) were obtained at baseline, three-, six-, and twelve months, lean mass at baseline and twelve months. Data were analysed with mixed linear regression model or robust cluster regression in an intention to treat analysis.

Results

Thirty-five women aged (mean ± SD) 69 ± 7) years were recruited of which thirty-two (91%) completed the twelve months follow-up (WBV + teriparatide = 15, teriparatide = 17). SPPB score (mean ± SD) improved significantly at three months in the WBV + teriparatide group from 9.13 ± 2.03 to 10.35 ± 1.69 (p = 0.014) with a statistical trend towards a between-group change in favor of the WBV + teriparatide group (0.86 [95%CI(- 0.05,1.77), p = 0.065]). Both groups improved in leg extension power during the study period whereas no changes were seen in TUG, grip strength, or lean mass in either group. No statistical significant between-group differences were observed.

Conclusion

WBV may improve some short-term aspects of physical performance in severely osteoporotic postmenopausal women who are receiving teriparatide treatment.

Trial Registration

ClinicalTrials.gov, ID:NCT02563353.

Authors+Show Affiliations

Department of Geriatric Medicine, Odense University Hospital, Odense, Denmark. Department of Clinical Research, University of Southern Denmark, Odense, Denmark.Department of Geriatric Medicine, Odense University Hospital, Odense, Denmark. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Department of Geriatric Medicine, Nottingham University Hospitals Trust NHS, Nottingham, UK.Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Department of Orthopaedics and Traumatology, Odense University Hospital, Odense, Denmark.Department of Endocrinology, Hospital South West Jutland, Esbjerg, Denmark. Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark. OPEN- Odense Patient data Explorative Network, Odense University Hospital/ University of Southern Denmark, Odense, Denmark.Department of Geriatric Medicine, Odense University Hospital, Odense, Denmark. Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32944251

Citation

Jepsen, Ditte Beck, et al. "The Combined Effect of Parathyroid Hormone (1-34) and Whole-body Vibration Exercise On Physical Performance in OSteoporotic Women (PaVOS Study): a Secondary Analysis From a Randomised Controlled Trial." BMC Sports Science, Medicine & Rehabilitation, vol. 12, 2020, p. 54.
Jepsen DB, Masud T, Holsgaard-Larsen A, et al. The combined effect of parathyroid hormone (1-34) and whole-body vibration exercise on physical performance in OSteoporotic women (PaVOS study): a secondary analysis from a randomised controlled trial. BMC Sports Sci Med Rehabil. 2020;12:54.
Jepsen, D. B., Masud, T., Holsgaard-Larsen, A., Hansen, S., Jørgensen, N. R., & Ryg, J. (2020). The combined effect of parathyroid hormone (1-34) and whole-body vibration exercise on physical performance in OSteoporotic women (PaVOS study): a secondary analysis from a randomised controlled trial. BMC Sports Science, Medicine & Rehabilitation, 12, 54. https://doi.org/10.1186/s13102-020-00204-w
Jepsen DB, et al. The Combined Effect of Parathyroid Hormone (1-34) and Whole-body Vibration Exercise On Physical Performance in OSteoporotic Women (PaVOS Study): a Secondary Analysis From a Randomised Controlled Trial. BMC Sports Sci Med Rehabil. 2020;12:54. PubMed PMID: 32944251.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The combined effect of parathyroid hormone (1-34) and whole-body vibration exercise on physical performance in OSteoporotic women (PaVOS study): a secondary analysis from a randomised controlled trial. AU - Jepsen,Ditte Beck, AU - Masud,Tahir, AU - Holsgaard-Larsen,Anders, AU - Hansen,Stinus, AU - Jørgensen,Niklas Rye, AU - Ryg,Jesper, Y1 - 2020/09/05/ PY - 2019/10/01/received PY - 2020/08/27/accepted PY - 2020/9/18/entrez PY - 2020/9/19/pubmed PY - 2020/9/19/medline KW - Exercise KW - Osteoporosis KW - Physical performance KW - Short physical performance battery KW - Whole-body vibration KW - Women SP - 54 EP - 54 JF - BMC sports science, medicine & rehabilitation JO - BMC Sports Sci Med Rehabil VL - 12 N2 - Background: The aim of this study was to investigate the effect on physical performance of combining whole-body vibration exercise (WBV) with parathyroid hormone 1-34 (teriparatide) compared to teriparatide alone. Methods: A secondary analysis from a RCT where postmenopausal women with severe osteoporosis were randomised to WBV plus teriparatide (intervention) or teriparatide alone (control). WBV was applied three times/week (6x1min WBV:1 min rest, (peak acceleration 3.6 g)) for twelve months. Both groups received teriparatide 20 μg s.c./day. The primary endpoint (bone mineral density) is reported elsewhere. Physical performance measures (Short Physical Performance Battery (SPPB), Timed-Up-and-Go (TUG), leg extension power, and grip strength) were obtained at baseline, three-, six-, and twelve months, lean mass at baseline and twelve months. Data were analysed with mixed linear regression model or robust cluster regression in an intention to treat analysis. Results: Thirty-five women aged (mean ± SD) 69 ± 7) years were recruited of which thirty-two (91%) completed the twelve months follow-up (WBV + teriparatide = 15, teriparatide = 17). SPPB score (mean ± SD) improved significantly at three months in the WBV + teriparatide group from 9.13 ± 2.03 to 10.35 ± 1.69 (p = 0.014) with a statistical trend towards a between-group change in favor of the WBV + teriparatide group (0.86 [95%CI(- 0.05,1.77), p = 0.065]). Both groups improved in leg extension power during the study period whereas no changes were seen in TUG, grip strength, or lean mass in either group. No statistical significant between-group differences were observed. Conclusion: WBV may improve some short-term aspects of physical performance in severely osteoporotic postmenopausal women who are receiving teriparatide treatment. Trial Registration: ClinicalTrials.gov, ID:NCT02563353. SN - 2052-1847 UR - https://www.unboundmedicine.com/medline/citation/32944251/The_combined_effect_of_parathyroid_hormone__1_34__and_whole_body_vibration_exercise_on_physical_performance_in_OSteoporotic_women__PaVOS_study_:_a_secondary_analysis_from_a_randomised_controlled_trial_ L2 - https://bmcsportsscimedrehabil.biomedcentral.com/articles/10.1186/s13102-020-00204-w DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.